Cardiovascular health five years after MIS-C in children
Official title: Cardiovascular Evaluation 5 Years After Multisystem Inflammatory Syndrome in Children (MIS-C)
Run by Medical University of Warsaw · NCT07659847 · Data updated 2026-11-12
This study tests whether kids who had MIS-C still show cardiovascular differences five years later compared with healthy peers.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Medical University of Warsaw Academic / other |
| Locations | 1 site (Warsaw, Masovian Voivodeship) |
| Status | Recruiting |
| Started | November 22, 2025 |
| Main results expected | October 31, 2026 |
| Study ends | March 31, 2027 |
| Registry record updated | June 22, 2026 |
| Trial ID | NCT07659847 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children and adolescents who previously had MIS-C and were hospitalized at the Medical University of Warsaw between October 2020 and February 2021, plus age- and sex-mec matching healthy controls.
✕Probably not a fit
Individuals with no history of MIS-C or those with significant pre-existing heart disease or chronic conditions may not derive a cardiovascular benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This cross-sectional study compares cardiovascular health in individuals five years after MIS-C to age- and sex-matched healthy controls. Researchers will use imaging, vascular assessments, cardiopulmonary exercise testing, and biomarkers of endothelial injury to characterize long-term cardiovascular status. The study builds on prior follow-up at two years by examining whether subclinical abnormalities persist into longer-term follow-up. Participants with a history of MIS-C were hospitalized at a Warsaw pediatric center between late 2020 and early 2021, and controls are recruited from primary care clinics. No interventions are being tested; the goal is to describe long-term cardiovascular outcomes in a real-world setting.
Why it matters
Potential benefit: If successful, the study could clarify whether MIS-C survivors require ongoing cardiovascular monitoring years after infection.
How similar studies have gone: Earlier follow-up suggested persistent subclinical cardiovascular changes; this study extends observation to five years to confirm durability of findings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * For the MIS-C group: History of MIS-C diagnosed according to World Health Organization (WHO) criteria * For all participants: Written informed consent from a parent or legal guardian and, where applicable, assent/consent from participants aged 16 years or older / Exclusion Criteria: MIS-C group: 1. Known heart disease, including congenital heart disease. 2. Significant chronic disease affecting growth, development, or daily functioning. Control group: 1. Elimination diet. 2. Competitive athletic training. 3. Known heart disease, including congenital heart disease. 4. Significant chronic disease affecting growth, development, or daily functioning.
Where it's running
-
Medical University of Warsaw Children's Clinical Hospital
Warsaw, Masovian Voivodeship, Poland Recruiting
Study contacts
- Study coordinator: Weronika Woźniak-Szewczyk, MD
- Email: wwozniakszewczyk@gmail.com
- Phone: +48 22 317 9231
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Remdesivir to prevent severe COVID-19 in kidney transplant patients
This study will try giving remdesivir around the time of transplant to see if it prevents severe COVID-19 in adults receiving a kidney transplant who are currently SARS‑CoV‑2 positive with no or mild symptoms.
-
2-HOBA to reduce persistent immune activation in Long COVID with POTS
This trial will test whether 2‑HOBA, a compound that scavenges harmful IsoLG-adducts, can reduce immune activation in adults with Long COVID who have POTS.
-
TFH-targeting COVID-19 booster vaccines with and without the 's3' component
This trial will test two experimental COVID-19 booster vaccines — one with an added 's3' component and one without — in healthy adults 40–64 to see if 's3' makes immune responses bigger, broader, and longer-lasting and to check safety.
-
Evaluating Baricitinib for Long COVID Symptoms
This study is testing if the medication baricitinib can help adults with Long COVID feel better physically and mentally compared to a placebo.
-
Study on influenza and COVID-19 effects in pregnant women in India
This study is testing how getting both COVID-19 and influenza affects pregnant women and their babies, while also looking at how vaccinations might help reduce risks during pregnancy.
-
Testing a new method to detect COVID-19 using exhaled air
This study is testing a new breath test for COVID-19 to see if it works as well as the traditional nose swab method, especially for people showing symptoms or who have been around someone infected.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.